AbbVie’s Growth Now Leans On A Single Molecule

SKYRIZI supplies close to a third of guided company revenue, which puts an unusual amount of AbbVie’s future behind one patent estate.

AbbVie (ABBV) has guided total 2026 revenue to roughly $67.6 billion. About $21.7 billion of that, close to one-third, is expected to come from a single medicine, SKYRIZI. That share is the number a holder should sit with before anything else in this story.

The $21.7 Billion Line Inside A $67.6 Billion Revenue Guide

The quarterly picture has the same shape. SKYRIZI sold $5.5 billion in the second quarter of 2026, up 24% operationally, against total net revenues of nearly $17 billion, and the next largest product AbbVie broke out, RINVOQ, sold more than $2.5 billion. Immunology as a whole brought in nearly $8.8 billion, more than half the company, on 14.6% operational growth. What makes that concentration matter is what sits beside it: oncology revenue of more than $1.6 billion fell 2.4% operationally in the same three months, and aesthetics, at nearly $1.3 billion, slipped 0.9%. Neuroscience did grow, at more than $3.2 billion and roughly 20%. So the growth you are paying for sits in immunology and neuroscience, and inside the bigger of the two it leans mostly on one molecule.

What The $756 Million HUMIRA Line Already Tells You

AbbVie does not have to imagine what biosimilar entry does to a large immunology franchise, because it is happening on its own income statement right now. HUMIRA sold $756 million in the second quarter of 2026, down 36% operationally, which the company puts down to biosimilar competition. A franchise shedding better than a third of its sales year over year is the shape of the risk, not its timing, because the two products sit on very different clocks.

SKYRIZI’s clock is public and much further out. The company says the US composition-of-matter patent expires in 2033, that later-expiring patents embodying the product are granted or in process and run into the mid twenty-thirties and later, that regulatory data protection does not lapse until 2031, and that it does not expect biosimilar applications before the end of the decade. That is a long runway by any standard. It is also why the question keeps coming back, because close to a third of today’s guided revenue eventually sits behind that later intellectual property rather than behind the original patent.

How Much Should That Third Worry You At $251

Honestly, not much on a two-year view, and the past year of trading has not priced it as a problem. ABBV trades at $250.94, up 37% over the past 12 months against 18.7% for the S&P 500, and sits at about 95% of its 52-week high of $263, with a market value of about $444 billion. A business whose revenue grew 10.2% year over year in the second quarter of 2026 is not one you sell over a patent date in 2033. The honest reading is narrower than that: you own a good company whose growth is unusually undiversified, and the part you cannot control is a calendar.

Two things would change the read. The first is whether oncology and aesthetics stop shrinking, which would make the one-molecule dependence a phase rather than a structure. The second is the US decision on SKYRIZI’s subcutaneous induction option in Crohn’s disease, which the company expects in the fall and says should meaningfully accelerate the franchise, in other words deepen the concentration before it eases. The trailing return says nothing about the months ahead, and the options market is already pricing unusual uncertainty here, with implied volatility at 28%, in the 85th percentile of its trailing one-year range. A screen for how much movement is being priced around the next catalyst is the practical way to size what that would cost you.

Owning The Right Company Does Not Fix Owning One Patent

The verdict above is that AbbVie is executing well and that the concentration is a structural fact rather than a near-term threat. Owning more AbbVie does not change any of that. One molecule, one patent estate, and one expiry schedule are precisely the kind of exposure you cannot net out inside a single holding. That is the case for a rules-based portfolio: the Trefis High Quality Portfolio buys quality on fixed rules and spreads the outcome across names, so no single expiry date decides how you do. That portfolio has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.